Physician profile
Thomas Peacock
NPI 1528063195
$392.53
in general payments reported to CMS, 2019-2025
12 companies · $60.55 in 2025
The $60.55 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.99 · 2021: $69.91 · 2022: $187 · 2023: $51.44 · 2025: $60.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $100.80 | 2022 | |
| Amgen INC. | $43.70 | 2019-2023 | Nplate, Xgeva |
| Ipsen Biopharmaceuticals, INC | $40.04 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.06 | 2025 | |
| Merck Sharp & Dohme LLC | $31.73 | 2023 | Keytruda |
| Incyte Corporation | $28.49 | 2025 | Monjuvi |
| Genzyme Corporation | $27.96 | 2022 | |
| Janssen Biotech, INC. | $21.41 | 2022 | |
| Glaxosmithkline, LLC. | $17.81 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $17.67 | 2022 | |
| Foundation Medicine, INC. | $15.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Peacock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.